Controlled Release of Glucosamine from Pluronic-Based Hydrogels for the Treatment of Osteoarthritis

Authors: Papon Thamvasupong, Kwanchanok Viravaidya-Pasuwat

Abstract:

Osteoarthritis affects a lot of people worldwide. Local injection of glucosamine is one of the alternative treatment methods to replenish the natural lubrication of cartilage. However, multiple injections can potentially lead to possible bacterial infection. Therefore, a drug delivery system is desired to reduce the frequencies of injections. A hydrogel is one of the delivery systems that can control the release of drugs. Thermo-reversible hydrogels can be beneficial to the drug delivery system especially in the local injection route because this formulation can change from liquid to gel after getting into human body. Once the gel is in the body, it will slowly release the drug in a controlled manner. In this study, various formulations of Pluronic-based hydrogels were synthesized for the controlled release of glucosamine. One of the challenges of the Pluronic controlled release system is its fast dissolution rate. To overcome this problem, alginate and calcium sulfate (CaSO₄) were added to the polymer solution. The characteristics of the hydrogels were investigated including the gelation temperature, gelation time, hydrogel dissolution and glucosamine release mechanism. Finally, a mathematical model of glucosamine release from Pluronic-alginate-hyaluronic acid hydrogel was developed. Our results have shown that crosslinking Pluronic gel with alginate did not significantly extend the dissolution rate of the gel. Moreover, the gel dissolution profiles and the glucosamine release mechanisms were best described using the zeroth-order kinetic model, indicating that the release of glucosamine was primarily governed by the gel dissolution.

Keywords: Controlled release, drug delivery system, glucosamine, Pluronic® F-127, thermoreversible hydrogel.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1125327

References:

[1] D. O. Clegg, et al., “Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis”, N. Engl. J. Med., vol. 354, no. 8, pp. 795 – 808, 2006.
[2] C. K. Kwok, et al., “Effect of oral glucosamine on joint structure in individuals with chronic knee pain: a randomized, placebo-controlled clinical trial”, Arthritis. Rheum., vol. 66, no. 4, pp. 930 – 939, 2014.
[3] K. Pal and D. K. Majumdar, “Polymeric Hydrogels: Characterization and Biomedical Applications –A mini review”, Des. Monomers and Polym., vol. 12, pp. 197 – 220, 2009.
[4] W. Zhang, et al., “Synthesis and Characterization of Thermally Responsive Pluronic F127 - Chitosan Nanocapsules for Controlled Release and Intracellular Delivery of Small Molecules”, ACSNANO, vol. 4, no. 11, pp. 6747 – 6759, 2010.
[5] M. Abrami, et al., “Physical Characterization of Alginate-Pluronic F127 Gel for Endoluminal NABDs Delivery”, Soft Matter., vol. 10, no. 5, pp. 729 – 737, 2014.
[6] Y. Wu, “Development of a Simple Analytical Methodology for Determination of Glucosamine Release from Modified Release Matrix Tablets”, J. Pharm. Bio. Anal., vol. 38, pp. 263 – 269, 2005.
[7] S. Dash, et al., “Kinetic Modeling on Drug Release from Controlled Drug Delivery Systems”, Acta Pol. Pharm., vol. 67, no. 3, pp. 217 – 223, 2010.
[8] T. R. Hoare and D. S. Kohane, “Hydrogels in Drug Delivery: Progress and Challenges”, Polymer, vol. 49, no. 8, pp. 1993 – 2007, 2008.
[9] C. Sandolo, et al., “Effect of Temperature and Cross-Linking Density on Rheology of Chemical Cross-Linked Guar Gum at the Gel Point”, Food Hydrocolloids, vol. 23, no. 1, pp. 210 – 220, 2009.
[10] K. Viravaidya, et al., “Pluronic Gel as a Controlled Delivery System for Doxorubicin, in Proc. 2nd Int. Conf. on Adv. Petrochem and Polym., Bangkok, 2007.
[11] C. Y. Gong, et al., “In Vitro Drug Release Behavior from a Novel Thermosensitive Composite Hydrogel Based on Pluronic F127”, BMC Biotechnol., vol. 9, no. 8, 2009.
[12] R. W. Korsmeyer, and N. A. Peppas, “Solute and Penetrant Diffusion in Swellable Polymer”, J. Control. Rel., vol. 1, pp. 89 – 98, 1987.
[13] M. A. Kalam, et al., Continental J. Pharm. Sci., vol. 1, pp. 30 – 35, 2007.
[14] J. Siepmann, and N. A. Peppas, Adv. Drug Deliv. Rev., vol. 48, pp. 139, 2001.
[15] P. L. Riger, and N. A. Peppas, J. Control. Rel., vol. 5, pp. 37, 1987.